NYSE:MTNB
Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. reported net income of −$10.3M in fiscal 2025. The diluted share count rose 12.5%.Summary generated from Matinas BioPharma Holdings, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−166.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+12.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3 | 1 | n/a | n/a |
| Operating income | −25 | −25 | −24 | −25 | −7 |
| Net income | −23 | −21 | −23 | −24 | −10 |
| Free cash flow | −15 | −20 | −15 | n/a | n/a |
Recent filings
- 8-KAmendment to articles or bylaws
Sep 28, 2026 - 8-KOther events
Sep 16, 2026 - 8-KNotice of delisting or listing-rule failure
Sep 4, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 4Insider transaction report
Aug 13, 2026 - 4Insider transaction report
Aug 13, 2026 - 8-KTermination of a material agreement
Jul 24, 2026 - 8-KEntry into a material agreement
Jul 13, 2026